Release of HMGB1 in response to pro-apoptotic glioma killing strategies: efficacy and neurotoxicity

PURPOSE: In preparation for a Phase I clinical trial utilizing a combined cytotoxic/immunotherapeutic strategy using adenoviruses expressing Flt3L (Ad-Flt3L) and thymidine kinase (Ad-TK) to treat glioblastoma (GBM), we tested the hypothesis that Ad-TK+GCV would be the optimal tumor killing agent in...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Candolfi, Marianela, Yagiz, Kader, Foulad, David, Alzadeh, Gabrielle E, Tesarfreund, Matthew, Muhammad, AKM G, Puntel, Mariana, Kroeger, Kurt M, Liu, Chunyan, Lee, Sharon, Curtin, James F, King, Gwendalyn D, Lerner, Jonathan, Sato, Katsuaki, Mineharu, Yohei, Xiong, Weidong, Lowenstein, Pedro R, Castro, Maria G
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2769255/
https://ncbi.nlm.nih.gov/pubmed/19570774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0155
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky